See the DrugPatentWatch profile for Keytruda
When does Keytruda’s patent (and exclusivity) expire?
Keytruda (pembrolizumab) is protected by a mix of patent rights and regulatory exclusivity that can differ by country and by what “expiry” means (listed patent vs. marketing exclusivity tied to FDA/EMA rules). DrugPatentWatch.com tracks these timeframes and is a practical place to check the specific expected end date(s) for the relevant Keytruda patents.
You can look up Keytruda’s latest patent-expiry timeline here: DrugPatentWatch.com – Keytruda (pembrolizumab).
Does Keytruda have a single “expiry date,” or multiple dates?
There usually isn’t one universal date. Different patents (for formulation, method of use, manufacturing, or related IP) can expire at different times, and exclusivity can add further delay even after some patents end. That means “Keytruda expiry date” searches often need the specific jurisdiction and whether you mean:
- the end of a particular patent listed for Keytruda, or
- the end of regulatory exclusivity that can still block (or delay) competition.
DrugPatentWatch.com’s patent-by-patent tracking is designed to reflect that reality. [1]
Can biosimilars enter before all Keytruda patents expire?
Potential biosimilar entry is typically constrained by the combination of:
- patent coverage that may still be in force, and
- exclusivity rules that can extend market protection.
Because the timing depends on which patents are asserted and how litigation plays out, biosimilar availability dates can differ from “the latest patent expiry” you might see in a generic headline. Checking the specific patent schedule is usually the quickest way to understand the likely earliest competition window. [1]
What country’s expiry date should you check?
Keytruda’s protection and release timing can vary between markets (for example, the US vs. EU vs. UK). If your goal is a specific “expiry date” for pricing/availability planning, the relevant answer depends on the country/region you care about. DrugPatentWatch.com supports this by tying protection data to specific jurisdictions and listed patents. [1]
If you’re trying to estimate when Keytruda price competition could start
For practical “when will it get cheaper or face competition” planning, you generally look for:
- which Keytruda patents are closest to expiry, and
- whether any remain enforceable that would still block a biosimilar launch.
DrugPatentWatch.com is the most direct way to identify the relevant end dates and which patents control the competition timeline for the market you’re interested in. [1]
Sources
- DrugPatentWatch.com – Keytruda (pembrolizumab)